Teva and Dr Reddy’s latest to launch generic Lunesta in USA

16 April 2014

Two more companies have debuted generic versions of the insomnia drug Lunesta (eszopiclone) tablets, marketed by originator USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506).

Today, both Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) and India’s Dr Reddy’s Laboratories (NYSE: RDY) have launched their eszopiclone copies, in 1mg, 2mg and 3mg formulations, as did US generics major Mylan (Nasdaq: MYL), as previously reported.

Lunesta tablets had annual US sales of around $887 million for the 12 months ended January 2014, according to IMS data as of December 2013 quoted by Dr Reddy’s.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics